Gestational Diabetes Explained: HAPO Trial, Screening, and Postpartum Risk

The Glucose Challenge That Changed Obstetric Practice

Gestational diabetes mellitus (GDM) affects 6–9% of pregnancies in the United States — approximately 240,000 cases annually — making it among the most common medical complications of pregnancy, according to the American Diabetes Association's 2024 Standards of Care. The condition emerges when the pancreatic beta cells cannot overcome the progressive insulin resistance driven by placental hormones, primarily human placental lactogen (hPL), progesterone, and cortisol, all of which rise throughout the second and third trimesters. The fetus experiences chronic glucose excess that carries consequences extending decades after birth.

Screening: GCT vs. GTT

Two protocols exist for GDM diagnosis, and their use varies by country and clinical setting:

Two-step approach (US standard): A 50g glucose challenge test (GCT) is administered without dietary preparation at 24–28 weeks gestation. A 1-hour plasma glucose ≥130–140 mg/dL (threshold varies by institution) triggers a 3-hour, 100g oral glucose tolerance test (OGTT). GDM is diagnosed if two or more values on the OGTT exceed the Carpenter-Coustan thresholds: fasting ≥95, 1-hour ≥180, 2-hour ≥155, 3-hour ≥140 mg/dL.

One-step approach (WHO/IADPSG): A 75g, 2-hour OGTT is performed without prior screening. GDM is diagnosed if any single value exceeds: fasting ≥92, 1-hour ≥180, 2-hour ≥153 mg/dL. The International Association of Diabetes and Pregnancy Study Groups (IADPSG) adopted this approach directly from the HAPO trial data, accepting a lower diagnostic threshold that captures more cases.

The HAPO Trial: Continuous Risk Without a Safe Threshold

The Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study, published in the New England Journal of Medicine in 2008, enrolled 23,316 pregnant women across 15 international centers and performed blinded 75g OGTTs at 24–28 weeks. Unlike prior studies, HAPO was designed to examine outcomes across the entire glucose distribution — not just diagnosed diabetes. The central finding was unambiguous: there was no threshold below which higher glucose was safe. Each standard deviation increase in fasting glucose, 1-hour glucose, and 2-hour glucose was independently and continuously associated with:

• Birth weight above the 90th percentile (large for gestational age)
• Primary caesarean delivery
• Neonatal hypoglycemia
• Cord blood C-peptide above the 90th percentile (indicating fetal hyperinsulinism)

This continuous relationship was the direct basis for the lower IADPSG diagnostic thresholds. The controversy is whether diagnosing more women as having GDM — and subjecting them to monitoring and intervention — produces clinical benefit proportionate to the anxiety and medicalization costs, a debate that remains active.

Fetal Complications: Macrosomia and Beyond

Uncontrolled maternal hyperglycemia crosses the placenta; the fetal pancreas responds with hyperinsulinism. Insulin is a potent fetal growth hormone, producing macrosomia (birth weight >4,000 g or >90th percentile), particularly through preferential deposition of fat on the trunk and shoulders. The clinical consequence of macrosomia includes:

• Shoulder dystocia: Impaction of fetal shoulder behind the maternal pubic symphysis during delivery, occurring in approximately 5% of macrosomic births; can cause permanent brachial plexus injury (Erb's palsy).
• Neonatal hypoglycemia: Fetal hyperinsulinism persists transiently after cord clamping removes the glucose supply, causing blood glucose to drop to <40 mg/dL in newborns — potentially causing seizures if undetected.
• Neonatal polycythemia and jaundice: Fetal hyperinsulinism stimulates erythropoiesis; excess red cell breakdown causes neonatal hyperbilirubinemia.
• Long-term offspring risk: HAPO follow-up at age 10–11 showed higher rates of obesity and glucose intolerance in children of GDM mothers, suggesting intrauterine programming effects.

Postpartum Risk: The 50% Conversion Rate

GDM resolves at delivery in the vast majority of cases — but it is a powerful predictor of future type 2 diabetes. The landmark meta-analysis by Bellamy et al. (2009, The Lancet), pooling data from 675,455 women across 20 studies, found that women with GDM faced a 7.43-fold increased risk of type 2 diabetes compared to those with normoglycemic pregnancies. Approximately 50% of women with GDM develop type 2 diabetes within 5–10 years of their affected pregnancy. Progression is faster in Asian-origin women, those with obesity, and those who required insulin therapy during pregnancy.

Postpartum OGTT at 6–12 weeks is the recommended screening tool. Fasting glucose or HbA1c are reasonable alternatives if the OGTT cannot be completed. Breastfeeding reduces GDM recurrence and modestly lowers subsequent T2D risk. Metformin and lifestyle intervention show efficacy in postpartum women with prediabetes in secondary analyses of the DPP.

This article is for informational purposes only. Consult a qualified healthcare professional.